Data / Drug companies / Rasagiline
Rasagiline: 11 companies and 21 products in the FDA NDC directory
Rasagiline is listed in the FDA National Drug Code Directory by 11 companies, with 21 products in commercial distribution. 19 of the products (90.5%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, and the newest product started marketing on October 20, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 11
- Products
- 21
- Generic (ANDA) products
- 19 (90.5%)
- Application numbers
- 8
- Routes
- Oral
- openFDA record search
- api.fda.gov
Companies that list rasagiline
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Alvogen Inc. | 2 | tablet | Generic drugs (ANDA) | March 1, 2019 |
| Ascend Laboratories, LLC | 2 | tablet | Generic drugs (ANDA) | October 30, 2017 |
| Aurobindo Pharma Limited | 2 | tablet | Generic drugs (ANDA) | October 20, 2026 |
| Chartwell RX, LLC | 2 | tablet | Generic drugs (ANDA) | July 27, 2018 |
| Macleods Pharmaceuticals Limited | 2 | tablet | Generic drugs (ANDA) | June 29, 2024 |
| Micro Labs Limited | 2 | tablet | Generic drugs (ANDA) | April 3, 2019 |
| NorthStar Rx LLC | 2 | tablet | Generic drugs (ANDA) | April 17, 2018 |
| Remedyrepack Inc. | 2 | tablet | Generic drugs (ANDA) | August 25, 2026 |
| Teva Pharmaceuticals USA, Inc. | 2 | tablet | Authorized generics (NDA) | January 3, 2017 |
| Torrent Pharmaceuticals Limited | 2 | tablet | Generic drugs (ANDA) | November 15, 2025 |
| Bryant Ranch Prepack | 1 | tablet | Generic drugs (ANDA) | April 3, 2019 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 21 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 19 | 90.5% |
| Authorized generics (NDA) | 2 | 9.5% |
Pharmacologic classes
| Class | Products |
|---|---|
| Monoamine Oxidase Inhibitor | 21 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.